TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07927010: A Phase 2/3, Randomized, Double-Masked, Vehicle-Controlled, Dose-Ranging Clinical Trial to Evaluate the Efficacy and Safety of Once Daily Bevemipretide Ophthalmic Topical Solution in Subjects Who Have Dry Age-Related Mac

Sponsor: Mighty Therapeutics, Inc. · Phase: PHASE2/PHASE3 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 300 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$12,961,280

Rescue Site Savings

+$8,546,344

Unlock Full NCT07927010 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07927010 Rescue Dossier →